Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28965242 | 0.89 | CYP1A2 (0.50) | CYP1A2CYP2C19CNR2KMT2AKDM4E | |
| SCHEMBL26117581 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2C19CNR2KMT2AKDM4E | |
| SCHEMBL68535 | 0.83 | PDE10A (0.41) | KMT2AKDM4EALDH1A1L3MBTL1NPC1 | |
| SCHEMBL1458454 | 0.81 | ALDH1A1 (0.49) | CYP2C19KMT2AKDM4EALDH1A1TSHR | |
| SCHEMBL19166978 | 0.79 | ALDH1A1 (0.45) | CYP1A2KMT2AKDM4EALDH1A1MAPK1 | |
| SCHEMBL9204354 | 0.79 | CYP1A2 (0.44) | CYP1A2CYP2C19KMT2AKDM4EALDH1A1 | |
| SCHEMBL10184712 | 0.78 | KMT2A (0.53) | CYP1A2CYP2C19KMT2AKDM4EALDH1A1 | |
| SCHEMBL9201765 | 0.78 | CYP1A2 (0.43) | CYP1A2CYP2C19CNR2KMT2AKDM4E | |
| SCHEMBL1458362 | 0.78 | RIPK2 (0.41) | KMT2AKDM4EALDH1A1TSHRMEN1 | |
| SCHEMBL9196622 | 0.76 | CYP1A2 (0.43) | CYP1A2CYP2C19CNR2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076950-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12544364-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | NOEMA PHARMA AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4504733-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20240390339-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-11883385-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | NOEMA PHARMA AG (CH) | 2024-01-30 | — | — | US | disclosed |
| EP-4284381-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | Noema Pharma AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-117157077-A | Methods of treating childhood onset fluency disorders | 诺埃玛制药公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | NOEMA PHARMA AG (CH) | 2023-11-30 | — | — | US | disclosed |
| WO-2023194964-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-12 | — | — | WO | disclosed |
| CN-116137811-A | Use of phosphodiesterase 10 inhibitors for the treatment of dolles syndrome | 诺埃玛制药公司 | 2023-05-19 | — | — | CN | disclosed |
| US-20230149372-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4161526-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | Noema Pharma AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022162193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | NOEMA PHARMA AG (CH) | 2022-08-04 | — | — | WO | disclosed |
| WO-2021245280-A9 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2022-01-27 | — | — | WO | disclosed |
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883385-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | PDE2A, PDE3A, PDE5A | CYP1A2 1074/4885CYP2C19 455/4885CNR2 2878/4885 |
| US-20240390339-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | PDE2A, PDE3A, PDE5A | CYP1A2 1074/4885CYP2C19 455/4885CNR2 2878/4885 |
| US-20230149372-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | PDE2A, PDE3A, PDE5A | CYP1A2 1074/4885CYP2C19 455/4885CNR2 2878/4885 |
| US-12544364-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | PDE10A, PDE11A, PDE1A | CYP1A2 703/4885CYP2C19 342/4885CNR2 2405/4885 |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | CYP1A2 134/4885CYP2C19 87/4885CNR2 2568/4885 |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | PDE10A, PDE4A, PDE7B | CYP1A2 959/4885CYP2C19 1607/4885CNR2 3129/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | CYP1A2 978/4885CYP2C19 1383/4885CNR2 3725/4885 |
| US-20260076950-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | PDE10A, PDE11A, PDE3A | CYP1A2 1056/4885CYP2C19 547/4885CNR2 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.